**Core tip:** Solid pseudopapillary neoplasm (SPN) has been recognized by World Health Organization since 2010, and classified as a low malignant potential neoplasm. Such neoplasm is characterized by the presence of a mutation in the gene that encodes β-catenin. β-catenin is an important factor in the Wnt signaling pathway (β-catenin-dependent Wnt signaling). The identification of extrapancreatic SPN, especially in the mesentery, indicates a possible endoderm link between pancreatic progenitor cells and SPN cells.

INTRODUCTION
============

Solid pseudopapillary neoplasm (SPN) is a rare and indolent type of neoplasm that occurs in pancreas; SPN forms 0.3% to 2.7% of all pancreatic exocrine tumors. A large body of SPN indices are found in young female patients, and well-circumscribed. A margin negative surgical resection shows curative result in majority of cases\[[@B1]-[@B3]\]; recurrence after surgical resection is reported in 2% to 10% of patients\[[@B4],[@B5]\]. Patients with unresectable SPN may have a long-term survival (5 years), and require complex chemo- and radio-therapy treatments; the efficacy of adjuvant therapies in the SPN treatment remains largely unknown and a clinical challenge. Thus, it is important to differentiate the risk of recurrence in SPN patients. An extrapancreatic development of SPN is a rare incident; only 16 cases of extrapancreatic SPN have been reported so far worldwide (Table [1](#T1){ref-type="table"}). In the present article, we report a patient, in whom SPN was found in the mesentery; no invasion or attachments to adjacent organs was observed. To the best of our knowledge, this article is the first to report a SPN case in the mesentery.

###### 

Review of extra-pancreatic solid pseudopapillary neoplasm

  **Ref**.                    **Age**   **Sex**   **Location**      **Size (cm)**   **Procedure**   **Follow-up**
  --------------------------- --------- --------- ----------------- --------------- --------------- ---------------
  Miyazaki et al\[[@B19]\]    22        F         Retroperitoneum   7               Laparoscopy     6 mo NED
  Hibi et al\[[@B20]\]        45        M         Omentum           15              Laparoscopy     96 mo DOD
  Deshpande et al\[[@B21]\]   17        F         Left ovary        25.5            Open surgery    72 mo NED
                              57        F         Right ovary       3               Open surgery    NA
                              21        F         Left ovary        14              Open surgery    NA
  He et al\[[@B22]\]          39        F         Right ovary       6               Laparoscopy     36 mo NED
  Fukunaga et al\[[@B23]\]    46        F         Omentum           5               Laparoscopy     3 mo NED
  Ishikawa et al\[[@B24]\]    13        F         Mesocolon         4               Open surgery    36 mo NED
  Guo et al\[[@B25]\]         47        F         Retroperitoneum   16              Open surgery    14 mo NED
  Geng et al\[[@B26]\]        37        F         Retroperitoneum   8               Open surgery    NA
  Zhu et al\[[@B27]\]         22        F         Retroperitoneum   6               Laparoscopy     14 mo NED
  Chen et al\[[@B28]\]        47        F         Left ovary        6               Open surgery    18 mo NED
  Cheuk et al\[[@B29]\]       25        F         Right ovary       16.5            Open surgery    144 mo NED
  Walter et al\[[@B30]\]      32        F         Stomach           10              Open surgery    24 mo LWD
                              73        M         Duodenum          14              Open surgery    3 mo DOD
  Stoll et al\[[@B31]\]       48        F         Left ovary        8               Open surgery    9 mo NED
  Present case                40        M         Mesentery         28              Open surgery    48 mo DOD

NED: No evidence of disease; DOD: Dead of disease; LWD: Live with disease; NA: Not available; F: Female; M: Male.

CASE REPORT
===========

A 40-year-old Chinese male came to hospital on November 15, 2012. His main complaint was abdominal distention that lasted over 6 mo. His physical examination revealed a 30 cm soft mass in the abdomen. An abdominal computed tomography (CT) scan exhibited solid and mixed cystic lesions, measuring \> 28 cm diameter (Figure [1](#F1){ref-type="fig"}). Patient's blood test results were unremarkable. On November 22, 2012, the patient underwent an exploratory laparotomy, and the tumor protruding from the mesentery was completely excised. At that time, no invasion or attachments to adjacent organs was observed. In addition, the postoperative course was uneventful. The resected specimen of the mesenteric tumor was 25 cm × 15 cm × 28 cm, and showed a multilobulated structure with rich microvasculature. Microscopic characterization of the tumor showed that the tumor formation was a mix of solid and pseudopapillary areas. There was no evidence of pancreatic tissue in the analyzed sample. Further, the specimen was positive for alpha-1-antitrypsin, vimentin, CD56 and β-catenin immunostaining, whereas negative for S-100, neuron-specific enolase, E-cadherin, calretinin, progesterone receptor, chromogranin, and pancytokeration (Figure [2](#F2){ref-type="fig"}). Such results led to the diagnosis of SPN in the mesentery. Following 3.5 years, the patient continued to complain about abdominal distention and occasional polypnea. An abdominal CT scan exhibited multiple tumors in peritoneum, greater omentum, and colonic wall (Figure [3](#F3){ref-type="fig"}). Meanwhile, cells in the pleural effusion were found positive for alpha-1-antitrypsin, vimentin, CD56 and β-catenin. It was clear that the patient was suffering from recurrence of the disease. Before the surgical operation to clean the recurrent tumors, the patient received the treatment of 60 mg cisplatin by hyperthermic intraperitoneal chemotherapy (HIPEC). Unfortunately, there was no response to the treatment, and the patient was transferred to the palliative care unit. Soon after the patient's physical conditions worsened, we lost the patient on November 2016, 4 years after the initial surgery.

![An abdominal computed tomography scan exhibited solid and mixed cystic lesions, measuring \> 28 cm diameter (black arrow). The tumor was apart from the pancreas (white arrow).](WJGO-9-497-g001){#F1}

![Histological and immunohistochemical findings of the tumor (× 200). The tumor cells are arranged in solid sheets, pseudopapillary and microcysts (A and B: Hematoxylin-eosin stain), and are immunohistochemically positive for alpha-1-antitrypsin (C), β-catenin (D: Cytoplasmic and nuclear staining), CD56 (E), whereas negative for chromogranin (F).](WJGO-9-497-g002){#F2}

![An abdominal computed tomography scan exhibited multiple tumors in peritoneum, greater omentum, and colonic wall (white arrow).](WJGO-9-497-g003){#F3}

DISCUSSION
==========

SPN has been recognized by the WHO classification as a low malignant potential neoplasm in 2010\[[@B3]\]. It was first named as Gruber-Frantz tumor and after that it had been called the pancreatic solid papillary epithelial neoplasm, pancreatic papillary cystic neoplasm, pancreatic solid cystic tumor and solid pseudopapillary tumor. The differential diagnosis of SPN may include: pseudocyst, pancreatic mucinous neoplasms, well-differentiated ductal adenocarcinoma, pancreatic endocrine neoplasm, and acinic cell carcinoma. The pathogenesis of SPN remains unclear. Likewise, genetic events that contribute to the development of SPN are yet to be discovered. There are two basic proposals for the SPN origin: (1) genital ridge-related cells and (2) pancreatic progenitor cells\[[@B1],[@B6]\]. To note, an important proportion of SPN cases show mutations in the somatic β-catenin coding gene (*CTNNB1*)\[[@B7]-[@B9]\]. Such mutations can affect Wnt signaling pathways as well as self-renewal capability of stem cells\[[@B10]\]. SPN cells were reported to be positive for β-catenin, vimentin, alpha-1-anti-trypsin, CD10, CD56, and progesterone receptors by immunohistochemical analysis\[[@B11]\]; however this staining pattern fails to reveal a clear phenotypic relationship between SPN and any of the defined cell lineages of the pancreas. Thereby, it can be speculated as SPN cells show multipotential differentiation. According to the study concerned with the embryonic development of the human pancreas, dorsal and ventral pancreatic buds were reported to proliferate from gut epithelium of endoderm during the 4^th^ week of gestation. Dorsal pancreas fuses with ventral pancreas at the 7^th^ week of gestation due to the rotation of the stomach and duodenum development\[[@B12]\]. Identification of extrapancreatic SPN in the ovary, retroperitoneum and the omentum, as listed in Table [1](#T1){ref-type="table"}, indicates a possible endoderm link, substantiated by the migration of pancreas during embryogenesis. We therefore believe that extrapancreatic SPN originates from pancreatic progenitor cells.

In SPN patients, tumor resection confers an 8 year survival rate in 85% of cases; nevertheless, local recurrence or distant metastases can occur in some patients\[[@B13]\]. Histological and clinical parameters for prediction of disease recurrence after the initial surgical operation remain a challenge as there is still no consensus in the medical community. Many clinicians and researchers have been working to determine such criteria. For example, Kang et al\[[@B14]\] listed: (1) a tumor size larger than 8 cm; (2) cellular atypia; (3) vascular invasion; (4) perineural invasion; (5) systemic metastasis; and (6) peritoneal seeding as significant prognostic factors for tumor recurrence in a multicenter study. A case series study conducted by Yang et al\[[@B15]\] showed that vascular invasion, extra-pancreatic invasion, lymph node metastasis, and Ki-67 index ≥ 4% are associated with SPN recurrence. It is important to note that a rupture of the tumor or laparoscopic biopsy may seed the tumor cells into the peritoneal cavity, and could be an etiological factor responsible for the peritoneal recurrence\[[@B16]\]. Nonetheless, a recurrence prediction scoring model require more investigation. Such model will help clinicians to distinguish a high-risk group from low-risk group. Likewise, there is still no consensus on the treatment strategy in patients with SPN recurrence. A previous report described a 35 years old woman relapsing 8 mo after the resection of an SPN, which ruptured preoperatively. The patient firstly underwent a complete cytoreductive surgery, but relapsed within 8 mo, and received another cytoreductive surgery combined with HIPEC (oxaliplatin and irinotecan). At 31 mo of follow-up, the patient showed no evidence of disease recurrence\[[@B17]\]. Thus, a complete cytoreductive surgery combined with HIPEC stands as an important treatment solution for high-risk group of SPN. Further, another report concluded that SPN are radiosensitive, and can be successfully treated by using radiation therapy\[[@B18]\]. Future clinical and molecular studies are required to provide more precise tools to predict the biological behavior of SPN.

ARTICLE HIGHLIGHTS
==================

Case characteristics
--------------------

Abdominal distension.

Clinical diagnosis
------------------

Abdominal mass.

Differential diagnosis
----------------------

Pancreatic mucinous neoplasms.

Laboratory diagnosis
--------------------

All labs were within normal limits.

Imaging diagnosis
-----------------

Mesenchymal neoplasm.

Pathological diagnosis
----------------------

Solid pseudopapillary neoplasm (SPN).

Treatment
---------

Complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.

Related reports
---------------

Grading and staging play an important role in treatment and prognosis.

Term explanation
----------------

SPN: Solid pseudopapillary neoplasm.

Experiences and lessons
-----------------------

Future clinical and molecular studies are required to provide more precise tools to predict the biological behavior of SPN.
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